[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527653":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":43,"centralContacts":47,"locations":56,"responsibleParty":75,"collaborators":78,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":38,"enrollmentInfo":92,"targetDuration":38,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":38,"overallStatus":59,"whyStopped":38,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Losartan Group","EXPERIMENTAL","Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Losartan.",[13],"Drug: Losartan",{"label":15,"type":16,"description":17,"interventionNames":18},"Amlodipine Group","ACTIVE_COMPARATOR","Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Amlodipine.",[19],"Drug: Amlodipine",{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo Group","PLACEBO_COMPARATOR","Subjects with Coarctation of Aorta (COA) and high blood pressure will receive Placebo.",[25],"Drug: Placebo",[27,34,39],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Losartan","50mg administered orally once daily for 52 weeks.",[9],[33],"Cozaar",{"type":28,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Amlodipine","5mg Amlodipine administered orally once daily for 52 weeks.",[15],null,{"type":28,"name":40,"description":41,"armGroupLabels":42,"otherNames":38},"Placebo","Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.",[21],[44],{"name":45,"affiliation":5,"role":46},"Alexander Egbe, MBBS, MPH","PRINCIPAL_INVESTIGATOR",[48,53],{"name":49,"role":50,"phone":51,"phoneExt":38,"email":52},"ACHD Research Program","CONTACT","(507) 293-2565","RSTACHDRESPRG@mayo.edu",{"name":45,"role":50,"phone":54,"phoneExt":38,"email":55},"(507) 284-2520","Egbe.Alexander@mayo.edu",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-92.4699,44.02163,{"lat":69,"lon":68},[72,73,74],{"name":49,"role":50,"phone":51,"phoneExt":38,"email":52},{"name":45,"role":50,"phone":54,"phoneExt":38,"email":55},{"name":45,"role":46,"phone":38,"phoneExt":38,"email":38},{"type":46,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Alexander C. Egbe","Principal Investigator",[79],{"name":80,"class":81},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100527653","phase-3-a-study-of-angiotensin-ii-receptor-blocker-on-cardiovascular-remodeling-value-trial-100527653",false,"NCT06150560","A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)","A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta","VALUE","Inclusion Criteria:\n\n* B\u002FS1 hypertension\n* SBP 100-139 average based on 3 office measurements.\n* Age 18 or Older\n* Previous COA Repair\n\nExclusion Criteria:\n\n* Currently on beta blocker (BB) therapy\n* Pregnancy\u002Flactating\n* eGFR\\\u003C30\n* Hyperkalemia (serum potassium \\>5.5mmol\u002FL)\n* Severe Aortic or Mitral valve stenosis or regurgitation\n* Epicardial CAD diagnosis\n* Received antihypertensive medications within the past year","ALL","18 Years",{"count":93,"type":94},120,"ESTIMATED","INTERVENTIONAL",[97],"PHASE3","The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.",[100,101],"Coarctation of Aorta","High Blood Pressure","2025-07-30",{"date":104,"type":105},"2025-08-03","ACTUAL",{"date":107,"type":105},"2024-04-01",{"date":109,"type":94},"2028-06-01",{"name":5,"class":6},1]